The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 310.00
Bid: 307.00
Ask: 312.00
Change: 0.00 (0.00%)
Spread: 5.00 (1.629%)
Open: 311.00
High: 314.00
Low: 303.00
Prev. Close: 310.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Hutchison China Drug Application Accepted

Thu, 17th Sep 2020 21:35

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Hutchison China Meditech Ltd - China-based biopharmaceutical company - New drug application for surufatinib as a treatment for advanced pancreatic neuroendocrine tumours accepted for review by China National Medical Products Administration. Application supported by data from its Sanet-p phase 3 study in China.

----------

Securities Trust of Scotland PLC - Edinburgh-based investor - Appoints Troy Asset Management Ltd as investment manager with no change to investment objective. Portfolio to be managed by Tomasz Boniek and wider Troy team. Troy to waive management fee for 12 month and make ongoing contribution to cost of secretarial and administration services. Discount control mechanism to be introduced in order to protect shareholders from company trading at discount to net asset value.

----------

FIH Group PLC - Falkland Islands-based conglomerate - Maintains focus on cash management, with cash as at August end GBP14.1 million. Trading has been hurt by Co As lockdown eases, revenue in both businesses steadily recovers but is still well below prior year levels with "significant loss of revenue in both UK businesses" from Covid-19. Not proposing interim dividend after cancelling financial 2020 dividend. "We still expect to record a loss for the financial year, though, before the costs of redundancies, at a lower underlying level than when we reported to shareholders in June." At its AGM, resolution 8 - which relates to "the disapplication of pre-emption rights, to allot equity securities or sell treasury shares for cash without first offering them to existing shareholders, in circumstances other than for a specific acquisition or capital investment" - fails to pass as does not get required 75% of votes. Board to consult with shareholders to understand and seek to address concerns.

----------

Eden Research PLC - biopesticides and plastic-free formulation technology company - Collaborator Eastman Chemical Co gets authorisation to tell Cedroz in France. Cedroz is Eden's bionematicide, targeting free living parasitic worms called nematodes. French regulator also approves its Mevalone biofungicide for use in organic agriculture in France. Mevalone also gets authorisation for use on tale and wine grapes in Serbia through regional distributor K&N Efthymiadis. Mevalone is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops.

----------

ADM Energy PLC - natural resources investor with assets in Nigeria - Formerly submits bid with Nigerian Department of Petroleum Resources for marginal field in 2020 marginal field bid round. 57 marginal fields available to participating companies and ADM is participating in the bid round as strategic partner of OilBank International Ltd. "The company expects the bid round to be concluded by the end of Q4 2020 and will update the market in due course."

----------

Dev Clever Holdings PLC - software and technology group based in Tamworth - Signs three-year commercial partnership with mobile pool betting applications provider Low6. Partnership allow for full integration of Low6's 'PubWars' mobile quiz based pool betting app to be integrated with Dev Clever's Engage gamification platform and 'PubPal' service.Partnership to be funded by fee of GBP115,000 paid to Dev Celevr by Low6 plus ongoing revenue share.

----------

Beowulf Mining PLC - miner with projects in Finland, Sweden, and Kosovo - Notes findings of market assessment of Kallak North by Bo Arvidson. Highlights of assessment include that Kallak ore testwork "has produced an exceptionally high-grade magnetite concentrate" at 71.5% iron content plus only "minimal detrimental components". This makes Kallak the market leading high-grade product within all known and planned future producers. CEO Kurt Budge: "Benchmark iron ore prices climbed to around USD130 a dry metric tonne in late August, the highest level since 2014, and with prices set to remain strong for the remainder of the year, now is the time for the Swedish government to give Kallak the 'green light'."

----------

Prairie Mining Ltd - Poland-focused coal development firm - Receives valid application for small oversubscription of 16.1 million shares at AUD0.25 issued price, raising AUD4.0 million or around GBP2.3 million. Prairie to accept all valid application with no scale back.

----------

Cadence Minerals PLC - London-based mineral resources investment company - Notes first set of results from Hastings Technology Metals, its joint venture partner in the Yangibana rare earth project in Western Australia. First nine holes all hit economic mineralisation. Hastings COO Andrew Reid: "These results have exceeded our expectations, which are an excellent first step in defining what appears to be a significant new zone of mineralisation. With this initial shallow program, we have confirmed the presence of broad mineralised widths and extended known extents of Mineral Resources. All the deepest holes confirm mineralisation continues at depth." Cadence owns 30% of Yangibana, while Hastings owns the other 70%.

----------

Galileo Resources PLC - miner with projects in Botswana, Zambia and South Africa - Begins helicopter-borne electromagnetic survey over two of its tenures within its Kalahari Copper Belt project, Botswana. Preliminary results expected by end of October. CEO Colin Bird: "Our initial activities will be two-fold in that we will investigate an area to the northeast which shows good geophysical potential and an area in the midst of a recent discovery. I have no doubt that time will see the Kalahari Copper Belt region emerging as a significant copper producer, since it already hosts two new world class deposits."

----------

Pan African Resources PLC - African-focused gold producer - Remuneration committee recommends restructuring some its long-term incentive schemes in order to simplify and consolidate, improving retention capability. CEO, financial director, and other executives and prescribed officers agree to relinquish share options under current scheme. In lieu of the relinquishment, restricted B class shares in capital of OAR Gold Prop Ltd will be issues in terms of newly established B-share scheme. Pan African owns 49% share capital of PAR Gold.

----------

Highland Gold Mining Ltd - Russian gold miner - Fortiana Holdings Ltd gets regulatory clearance from Russian Federal Antimonopoly Service in connection with its mandatory cash offer for Highland Gold. Fortiana is to acquire 145.8 million shares in Highland Gold from eight shareholders at GBP3.00 each for a total of GBP437.4 million, giving Fortiana a 40% stake in Highland and valuing the whole company at GBP1.09 billion. It has also put forward an offer to acquire all Highland shares at the same price.

----------

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
3 May 2024 13:37

UK shareholder meetings calendar - next 7 days

Monday 6 May 
no events scheduled 
Tuesday 7 May 
Caledonia Mining Corp PLCAGM
CPPGroup PLCAGM
Just Group PLCAGM
Macfarlane Group PLC AGM
Plus500 LtdAGM
Supernova Digital Assets PLCAGM
Wednesday 8 May 
Airea PLCAGM
Antofagasta PLCAGM
Aston Martin Lagonda Global Holdings PLCAGM
Deltex Medical Group PLCAGM
Direct Line Insurance Group PLCAGM
Fidelity European Trust PLCAGM
Haleon PLCAGM
Jardine Matheson PLCAGM
JZ Capital Partners LtdEGM re investing in a secondary fund
Oscillate PLCAGM
Pershing Square Holdings LtdAGM
Rentokil Initial PLCAGM
WPP PLCAGM
Thursday 9 May 
Ascential PLCAGM
BAE Systems PLCAGM
Balfour Beatty PLCAGM
Barclays PLCAGM
CAB Payments Holdings PLCAGM
Catenai PLCGM re convertible loan note
Clarkson PLCAGM
FBD Holdings PLCAGM
Genel Energy plcAGM
Gym Group PLCAGM
Harbour Energy PLCAGM
Hiscox LtdAGM
IMI PLCAGM
Inchcape PLCAGM
Indivior PLCAGM
John Wood Group PLCAGM
Jupiter Fund Management PLCAGM
Logistics Development Group PLCAGM
Man Group PLCAGM
Morgan Advanced Materials PLCAGM
OSB Group PLCAGM
Public Policy Holding Co IncAGM
Rathbones Group PLCAGM
RM PLCAGM
Spire Healthcare Group PLCAGM
Synthomer PLCAGM
Uniphar PLCAGM
Friday 10 May 
Cairn Homes PLCAGM
Derwent London PLCAGM
Diversified Energy Co PLCAGM
Hutchmed China LtdAGM
Irish Residential Properties REIT PLCAGM
Kenmare Resources PLCAGM
Rightmove PLCAGM
Serinus Energy PLCAGM
Standard Chartered PLCAGM
Wheaton Precious Metals CorpAGM
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
26 Apr 2024 16:09

Hutchmed notes CHMP's positive opinion for fruiquintinib approval

(Alliance News) - Hutchmed (China) Ltd on Friday said that its partner Takeda Pharmaceutical Co Ltd has been notified that the Committee for Medicinal Products for Human Use of the European Medicines Agency recommends approval for fruquintinib.

Read more
5 Apr 2024 11:54

Hutchmed China to make several presentations at cancer research meeting

(Sharecast News) - Hutchmed China announced the upcoming presentation of new and updated data from various studies featuring compounds it had discovered on Friday, at the American Association of Cancer Research (AACR) annual meeting from 5 to 10 April in San Diego, California.

Read more
2 Apr 2024 12:11

Hutchmed endometrial cancer treatment gets priority review in China

(Sharecast News) - Hutchmed China announced the acceptance and granting of priority review by the China National Medical Products Administration (NMPA) for a new drug application combining fruquintinib and sintilimab for the treatment of advanced endometrial cancer on Tuesday.

Read more
2 Apr 2024 10:32

Hutchmed endometrial cancer treatment application accepted for review

(Alliance News) - Hutchmed (China) Ltd on Tuesday jointly announced with Innovent Biologics that their new drug application for the combined fruquintinib and sintilimab treatment for endometrial cancer has been granted priority review by the China National Medical Products Administration.

Read more
2 Apr 2024 08:05

LONDON BRIEFING: HSBC in special payout on Canada sale; Astra FDA win

(Alliance News) - London's FTSE 100 traded higher on Tuesday following the long weekend, as investors react to US data, and look ahead to manufacturing sector readings from Europe later.

Read more
28 Mar 2024 13:02

Hutchmed cancer treatment indication accepted for review in China

(Sharecast News) - Hutchmed China announced a significant milestone in its cancer treatment work on Thursday, with the supplemental new drug application (sNDA) for savolitinib had been accepted for review by the China National Medical Products Administration (NMPA).

Read more
28 Mar 2024 11:08

Hutchmed lung cancer treatment accepted for review in China

(Alliance News) - Hutchmed (China) Ltd on Thursday said its supplemental new drug application for savolitinib has been accepted for review by the China National Medical Products Administration.

Read more
28 Mar 2024 08:08

LONDON BRIEFING: JD Sports backs outlook; Spirent accepts new offer

(Alliance News) - Stocks in London traded higher early on Thursday in the final trading day of a holiday-shortened week, despite some hawkish words from a US central banker.

Read more
22 Mar 2024 10:09

Hutchmed begins registration stage for sovleplenib phase 2/3 trial

(Alliance News) - Hutchmed (China) Ltd on Friday said it initiated the registration stage of the phase 2/3 clinical trial for sovleplenib, its warm antibody autoimmune hemolytic anemia treatment.

Read more
28 Feb 2024 17:31

EARNINGS: Hutchmed revenue surges, Craven House's loss widens

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
21 Feb 2024 15:14

UK earnings, trading statements calendar - next 7 days

Thursday 22 February 
Anglo American PLCFull Year Results
Genus PLCHalf Year Results
Hargreaves Lansdown PLCHalf Year Results
Hays PLCHalf Year Results
Hikma Pharmaceuticals PLCFull Year Results
Indivior PLCFull Year Results
Jupiter Fund Management PLCFull Year Results
Lloyds Banking Group PLCFull Year Results
ME Group International PLCFull Year Results
Mondi PLCFull Year Results
Morgan Sindall Group PLCFull Year Results
Pantheon International PLCHalf Year Results
Rolls-Royce Holdings PLCFull Year Results
WPP PLCFull Year Results
Friday 23 February 
City of London Investment Group PLCHalf Year Results
Irish Residential Properties REIT PLCFull Year Results
Standard Chartered PLCFull Year Results
Monday 26 February 
Base Resources LtdHalf Year Results
Bunzl PLCFull Year Results
EnSilica PLCHalf Year Results
Kosmos Energy LtdFull Year Results
Made Tech Group PLCHalf Year Results
Tristel PLCHalf Year Results
Tuesday 27 February 
abrdn Equity Income Trust PLCFull Year Results
abrdn PLCFull Year Results
Croda International PLCFull Year Results
Kitwave Group PLCFull Year Results
McBride PLCHalf Year Results
PCI-PAL PLCHalf Year Results
Smith & Nephew PLCFull Year Results
Synectics PLCFull Year Results
Uniphar PLCFull Year Results
Unite Group PLCFull Year Results
Wednesday 28 February 
AB Dynamics PLCTrading Statement
ASA International Group PLCTrading Statement
Aston Martin Lagonda Global Holdings PLCFull Year Results
Avingtrans PLCHalf Year Results
Bluefield Solar Income Fund LtdHalf Year Results
Derwent London PLCFull Year Results
Glenveagh Properties PLCFull Year Results
Grit Real Estate Income Group LtdHalf Year Results
Hutchmed China LtdFull Year Results
International Personal Finance PLCFull Year Results
Just Eat Takeaway.com NVFull Year Results
Primary Health Properties PLCFull Year Results
Reckitt Benckiser Group PLCFull Year Results
Renewables Infrastructure Group LtdFull Year Results
RHI Magnesita NVFull Year Results
St James's Place PLCFull Year Results
Taylor Wimpey PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
7 Feb 2024 09:50

Hutchmed hails fruquintinib trial results for gastric cancer treatment

(Alliance News) - Hutchmed (China) Ltd on Wednesday said phase three data for fruquintinib in combination with paclitaxel showed an improvement in overall survival for patients with gastric or gastroesophageal junction adenocarcinoma.

Read more
2 Feb 2024 09:52

Hutchmed says Inmagene exercises option to licence drug candidates

(Alliance News) - Hutchmed (China) Ltd on Friday said Inmagene Biopharmaceuticals Ltd has exercised options to licence two drug candidates as part of a strategic partnership.

Read more
2 Feb 2024 09:42

Hutchmed partner Inmagene exercises options over two drug candidates

(Sharecast News) - Hutchmed China announced on Friday that Inmagene Biopharmaceuticals has exercised options to licence two drug candidates, IMG-007 and IMG-004, as part of their strategic partnership.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.